Oncology · Colorectal CancerTrial Updatecompetitivemid-term

Cadonilimab Targets PD-1/PD-L1 Blockade-Refractory MSI-H/dMMR Colorectal Cancer

Importance8/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/25/2026, 6:02:39 AM

Assessment confidence: 57% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The ongoing trial of Cadonilimab presents a significant opportunity to address a patient population that currently has limited treatment options due to resistance to existing PD-1 therapies. If successful, it could disrupt the market dynamics for colorectal cancer treatments, particularly impacting established therapies like pembrolizumab and nivolumab. Regulatory context from FDA (Janus Kinase (JAK) inhibitors: Drug Safety Communication - FDA Requires Warnings about Increased Risk of Serious Heart-related Events, Cancer, Blood Clots, and Death) supports the near-term read.

Strategic Assessment

If successful, Cadonilimab could capture market share from current therapies like pembrolizumab and nivolumab, particularly in the refractory patient population. The strongest clinical anchor is Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer (ClinicalTrials.gov), sub-indication match (colorectal cancer); mechanism alignment (pd-1). In colorectal cancer, 0 regulatory and 1 competitive items passed relevance filtering for Cadonilimab.

Competitive Pressure

The most relevant competitive pressure comes from Chemoimmunotherapy Shows Promise in MSS Colorectal Cancer: Pooled Analysis Insights (Humanexa Signals) — sub-indication match (colorectal cancer).

Regulatory Outlook

Regulatory risk is concentrated around The trial's results will be critical for potential regulatory approval, especially given the unique patient population it targets, which may influence future treatment guidelines and approvals..

Key Risks

Elevated medium regulatory exposure for Cadonilimab could delay market entry or constrain labeling if agency review intensifies.
Evidence gap: no medium- or high-relevance regulatory precedents in ingested corpus.
Signal severity is high — leadership review is warranted.

Key Opportunities

A successful outcome for Cadonilimab could lead to substantial market share capture from current therapies, particularly in the refractory patient segment, potentially resulting in increased revenue streams for the sponsoring company.
Upside for Cadonilimab may improve if Lidocaine enhances antitumor effects of sorafenib and GW5074 in colorectal cancer cells. (PubMed) delivers favorable follow-through.
If successful, Cadonilimab could capture market share from current therapies like pembrolizumab and nivolumab, particularly in the refractory patient population.

What Would Change This Assessment

This becomes more urgent if Monitor trial results for Cadonilimab, including efficacy and safety data, as well as competitive responses from existing PD-1 therapies.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Janus Kinase (JAK) inhibitors: Drug Safety Communication - FDA Requires Warnings about Increased Risk of Serious Heart-related Events, Cancer, Blood Clots, and Death
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Ongoing | Cancer Accelerated Approvals
FDAlow relevance
Regulatory pathway relevance (approval); Broad oncology match without sub-indication specificity
FDA document
View source
Withdrawn | Cancer Accelerated Approvals
FDAlow relevance
Regulatory pathway relevance (approval); Broad oncology match without sub-indication specificity
FDA document
View source
Oncology (Cancer)/Hematologic Malignancies Approval Notifications
FDAlow relevance
Regulatory pathway relevance (approval); Broad oncology match without sub-indication specificity
FDA document
View source

Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer
ClinicalTrials.govhigh relevance
Sub-indication match (colorectal cancer); Mechanism alignment (PD-1)
FDA document
View source
A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers
ClinicalTrials.govmedium relevance
Sub-indication match (colorectal cancer)
FDA document
View source
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
ClinicalTrials.govlow relevance
Entity match (pembrolizumab)
FDA document
View source
Minimally Invasive Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Cancer, SOS5C Trial
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Trea
ClinicalTrials.govlow relevance
Broad oncology match without sub-indication specificity
FDA document
View source

Chemoimmunotherapy Shows Promise in MSS Colorectal Cancer: Pooled Analysis Insights
Humanexa Signalsmedium relevance
Sub-indication match (colorectal cancer)

Pooled analysis of 2 clinical trials of first-line chemoimmunotherapy for metastatic microsatellite stable colorectal cancer MEDITREME and METIMMOX studies.
PubMedhigh relevance
Sub-indication match (colorectal cancer); Mechanism alignment (PD-1)
FDA document
View source
MBD2 suppresses SFRP1 expression and promotes colorectal cancer development by blocking MED19 binding to its methylated promoter.
PubMedmedium relevance
Sub-indication match (colorectal cancer)
FDA document
View source
An orthotopic organoid-based model to study early CD8⁺ T cell dysfunction and immunotherapy response in colorectal cancer.
PubMedmedium relevance
Sub-indication match (colorectal cancer)
FDA document
View source
Cost-effectiveness of multitarget stool DNA testing for colorectal cancer screening in Chinese primary healthcare settings: a modelling study.
PubMedmedium relevance
Sub-indication match (colorectal cancer)
FDA document
View source
ADAR1-circRAB5A-BIP axis governs radiotherapy resistance in colorectal cancer through coordinating protective autophagy and apoptosis.
PubMedmedium relevance
Sub-indication match (colorectal cancer)
FDA document
View source
Risk Factors, Cancer Types and Prognostic Significance of Second Primary Cancer After Early-, Intermediate- and Late-Onset Colorectal Cancer: A Retrospective Study in Chinese High-Volume Cancer Center
PubMedmedium relevance
Sub-indication match (colorectal cancer)
FDA document
View source
Lidocaine enhances antitumor effects of sorafenib and GW5074 in colorectal cancer cells.
PubMedmedium relevance
Sub-indication match (colorectal cancer)
FDA document
View source
Elevated ESR2 and BRCA1 gene expression in adenomyosis associated with endometrial cancer: a pilot study.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Cadonilimab
pembrolizumab
nivolumab

Commercial impact

high

A successful outcome for Cadonilimab could lead to substantial market share capture from current therapies, particularly in the refractory patient segment, potentially resulting in increased revenue streams for the sponsoring company.

Regulatory impact

medium

The trial's results will be critical for potential regulatory approval, especially given the unique patient population it targets, which may influence future treatment guidelines and approvals.

What to watch

Monitor trial results for Cadonilimab, including efficacy and safety data, as well as competitive responses from existing PD-1 therapies.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.